{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:44:40Z","timestamp":1794897880658,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Korea Health Technology R"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Elevation of total cell-free DNA (cfDNA) in patients with preeclampsia is well-known; however, whether this change precedes the onset of symptoms remains inconclusive. Here, we conducted a nested case\u2013control study to determine the elevation of cfDNA levels in women who subsequently developed preeclampsia. Methylated <jats:italic>HYP2<\/jats:italic> (m-<jats:italic>HYP2<\/jats:italic>) levels were determined in 68 blood samples collected from women with hypertensive disorders of pregnancy, along with 136 control samples, using real-time quantitative PCR. The measured m-<jats:italic>HYP2<\/jats:italic> levels were converted to multiples of the median (MoM) values for correction of maternal characteristics. The m-<jats:italic>HYP2<\/jats:italic> levels and MoM values in patients with preeclampsia were significantly higher than in controls during the third trimester (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, both), whereas those for women who subsequently developed preeclampsia did not differ during the second trimester. However, when patients with preeclampsia were divided based on the onset-time of preeclampsia or 10th percentile birth weight, both values were significantly higher in women who subsequently developed early-onset preeclampsia (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05, both) and preeclampsia with small-for-gestational-age (SGA) neonate (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01, both) than controls. These results suggested that total cfDNA levels could be used to predict early-onset preeclampsia or preeclampsia with SGA neonate.<\/jats:p>","DOI":"10.1038\/s41598-020-68842-1","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T10:04:22Z","timestamp":1594893862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction"],"prefix":"10.1038","volume":"10","author":[{"given":"Dong Wook","family":"Kwak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyae","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Mee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"68842_CR1","first-page":"181","volume":"102","author":"BM Sibai","year":"2003","unstructured":"Sibai, B. M. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 102, 181\u2013192 (2003).","journal-title":"Obstet Gynecol."},{"key":"68842_CR2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","volume":"376","author":"EA Steegers","year":"2010","unstructured":"Steegers, E. A., von Dadelszen, P., Duvekot, J. J. & Pijnenborg, R. Pre-eclampsia. Lancet 376, 631\u2013644 (2010).","journal-title":"Lancet"},{"key":"68842_CR3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","volume":"216","author":"S Roberge","year":"2017","unstructured":"Roberge, S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am. J. Obstet. Gynecol. 216, 110\u2013120 (2017).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"68842_CR4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajog.2016.10.016","volume":"216","author":"S Meher","year":"2017","unstructured":"Meher, S., Duley, L., Hunter, K. & Askie, L. Antiplatelet therapy before or after 16 weeks\u2019 gestation for preventing preeclampsia: an individual participant data meta-analysis. Am. J. Obstet. Gynecol. 216, 121\u2013128 (2017).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"68842_CR5","doi-asserted-by":"crossref","first-page":"i1753","DOI":"10.1136\/bmj.i1753","volume":"353","author":"E Bartsch","year":"2016","unstructured":"Bartsch, E. et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 353, i1753 (2016).","journal-title":"BMJ"},{"key":"68842_CR6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/uog.13275","volume":"43","author":"L Velauthar","year":"2014","unstructured":"Velauthar, L. et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women. Ultrasound Obstet. Gynecol. 43, 500\u2013507 (2014).","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"68842_CR7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/10641955.2016.1139719","volume":"35","author":"A Mabuchi","year":"2016","unstructured":"Mabuchi, A. et al. Significance of high-normal blood pressure during early second trimester for predicting the onset of hypertensive disorders in pregnancy. Hypertens. Pregnancy 35, 234\u2013241 (2016).","journal-title":"Hypertens. Pregnancy"},{"key":"68842_CR8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/AOG.0b013e3181719b7a","volume":"111","author":"JH Lim","year":"2008","unstructured":"Lim, J. H. et al. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet. Gynecol. 111, 1403\u20131409 (2008).","journal-title":"Obstet. Gynecol."},{"key":"68842_CR9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/pd.2217","volume":"29","author":"JH Lim","year":"2009","unstructured":"Lim, J. H. et al. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia. Prenat. Diagn. 29, 471\u2013476 (2009).","journal-title":"Prenat. Diagn."},{"key":"68842_CR10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1471-0528.2012.03311.x","volume":"119","author":"CE Kleinrouweler","year":"2012","unstructured":"Kleinrouweler, C. E. et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 119, 778\u2013787 (2012).","journal-title":"BJOG"},{"key":"68842_CR11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/pd.4397","volume":"34","author":"LC Poon","year":"2014","unstructured":"Poon, L. C. & Nicolaides, K. H. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat. Diagn. 34, 618\u2013627 (2014).","journal-title":"Prenat. Diagn."},{"key":"68842_CR12","first-page":"178","volume":"7","author":"R Levy","year":"2005","unstructured":"Levy, R. The role of apoptosis in preeclampsia. Isr. Med. Assoc. J. 7, 178\u2013181 (2005).","journal-title":"Isr. Med. Assoc. J."},{"key":"68842_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1081\/PRG-120002911","volume":"21","author":"XY Zhong","year":"2002","unstructured":"Zhong, X. Y., Holzgreve, W. & Hahn, S. The concentrations of circulatory fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens. Pregnancy 21, 77\u201383 (2002).","journal-title":"Hypertens. Pregnancy"},{"key":"68842_CR14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/pd.788","volume":"24","author":"A Farina","year":"2004","unstructured":"Farina, A. et al. Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat. Diagn. 24, 83\u201386 (2004).","journal-title":"Prenat. Diagn."},{"issue":"472","key":"68842_CR15","first-page":"e1","volume":"201","author":"S Sifakis","year":"2009","unstructured":"Sifakis, S., Zaravinos, A., Maiz, N., Spandidos, D. A. & Nicolaides, K. H. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am. J. Obstet. Gynecol. 201(472), e1-7 (2009).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"68842_CR16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.placenta.2012.11.001","volume":"34","author":"MJ Kim","year":"2013","unstructured":"Kim, M. J. et al. Association of fetal-derived hypermethylated RASSF1A concentration in placenta-mediated pregnancy complications. Placenta 34, 57\u201361 (2013).","journal-title":"Placenta"},{"key":"68842_CR17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40291-016-0245-9","volume":"21","author":"E Contro","year":"2017","unstructured":"Contro, E., Bernabini, D. & Farina, A. Cell-free fetal DNA for the prediction of pre-eclampsia at the first and second trimesters: a systematic review and meta-analysis. Mol. Diagn. Ther. 21, 125\u2013135 (2017).","journal-title":"Mol. Diagn. Ther."},{"key":"68842_CR18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/bloodadvances.2018018895","volume":"3","author":"AJ van der Meer","year":"2019","unstructured":"van der Meer, A. J. et al. Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans. Blood Adv. 3, 724\u2013728 (2019).","journal-title":"Blood Adv."},{"key":"68842_CR19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1067\/mob.2003.27","volume":"188","author":"A Sekizawa","year":"2003","unstructured":"Sekizawa, A. et al. Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am. J. Obstet. Gynecol. 188, 480\u2013484 (2003).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"68842_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/1471-2350-10-120","volume":"10","author":"L Lazar","year":"2009","unstructured":"Lazar, L. et al. Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia. BMC Med. Genet. 10, 120 (2009).","journal-title":"BMC Med. Genet."},{"key":"68842_CR21","doi-asserted-by":"crossref","first-page":"e0200360","DOI":"10.1371\/journal.pone.0200360","volume":"13","author":"T Rafaeli-Yehudai","year":"2018","unstructured":"Rafaeli-Yehudai, T. et al. Maternal total cell-free DNA in preeclampsia and fetal growth restriction: evidence of differences in maternal response to abnormal implantation. PLoS ONE 13, e0200360 (2018).","journal-title":"PLoS ONE"},{"key":"68842_CR22","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.placenta.2015.07.003","volume":"36","author":"F Salvianti","year":"2015","unstructured":"Salvianti, F. et al. Prospective evaluation of RASSF1A cell-free DNA as a biomarker of preeclampsia. Placenta 36, 996\u20131001 (2015).","journal-title":"Placenta"},{"key":"68842_CR23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/pd.973","volume":"24","author":"A Farina","year":"2004","unstructured":"Farina, A. et al. Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening. Prenat. Diagn. 24, 722\u2013726 (2004).","journal-title":"Prenat. Diagn."},{"key":"68842_CR24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000444524","volume":"40","author":"SY Kim","year":"2016","unstructured":"Kim, S. Y. et al. Early prediction of hypertensive disorders of pregnancy using cell-free fetal DNA, cell-free total DNA, and biochemical markers. Fetal Diagn. Ther. 40, 255\u2013262 (2016).","journal-title":"Fetal Diagn. Ther."},{"key":"68842_CR25","first-page":"191","volume":"34","author":"RM Silver","year":"2017","unstructured":"Silver, R. M. et al. Cell-free total and fetal DNA in first trimester maternal serum and subsequent development of preeclampsia. Am. J. Perinatol. 34, 191\u2013198 (2017).","journal-title":"Am. J. Perinatol."},{"key":"68842_CR26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/uog.18993","volume":"52","author":"DL Rolnik","year":"2018","unstructured":"Rolnik, D. L., da Silva Costa, F., Lee, T. J., Schmid, M. & McLennan, A. C. Association between fetal fraction on cell-free DNA testing and first-trimester markers for pre-eclampsia. Ultrasound Obstet. Gynecol. 52, 722\u2013727 (2018).","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"68842_CR27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.preghy.2019.04.002","volume":"16","author":"KD Genson","year":"2019","unstructured":"Genson, K. D. et al. Low fetal fraction of cell-free DNA predicts placental dysfunction and hypertensive disease in pregnancy. Pregnancy Hypertens. 16, 148\u2013153 (2019).","journal-title":"Pregnancy Hypertens."},{"key":"68842_CR28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/uog.14671","volume":"45","author":"DL Rolnik","year":"2015","unstructured":"Rolnik, D. L. et al. Maternal plasma cell-free DNA in the prediction of preeclampsia. Ultrasound Obstet. Gynecol. 45, 106\u2013111 (2015).","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"68842_CR29","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/0002-9378(93)90265-K","volume":"169","author":"B Eskenazi","year":"1993","unstructured":"Eskenazi, B., Fenster, L., Sydney, S. & Elkin, E. P. Fetal growth retardation in infants of multiparous and nulliparous women with preeclampsia. Am. J. Obstet. Gynecol. 169, 1112\u20131118 (1993).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"68842_CR30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/OGX.0b013e3182331028","volume":"66","author":"D Raymond","year":"2011","unstructured":"Raymond, D. & Peterson, E. A critical review of early-onset and late-onset preeclampsia. Obstet. Gynecol. Surv. 66, 497\u2013506 (2011).","journal-title":"Obstet. Gynecol. Surv."},{"key":"68842_CR31","first-page":"575","volume":"101","author":"S Rasmussen","year":"2003","unstructured":"Rasmussen, S. & Irgens, L. M. Fetal growth and body proportion in preeclampsia. Obstet. Gynecol. 101, 575\u2013583 (2003).","journal-title":"Obstet. Gynecol."},{"key":"68842_CR32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.placenta.2004.04.011","volume":"25","author":"TM Mayhew","year":"2004","unstructured":"Mayhew, T. M., Wijesekara, J., Baker, P. N. & Ong, S. S. Morphometric evidence that villous development and fetoplacental angiogenesis are compromised by intrauterine growth restriction but not by pre-eclampsia. Placenta 25, 829\u2013833 (2004).","journal-title":"Placenta"},{"issue":"Suppl 2","key":"68842_CR33","first-page":"1","volume":"49","author":"HA Wollmann","year":"1998","unstructured":"Wollmann, H. A. Intrauterine growth restriction: definition and etiology. Horm. Res. 49(Suppl 2), 1\u20136 (1998).","journal-title":"Horm. Res."},{"key":"68842_CR34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/10641955.2016.1212872","volume":"35","author":"J Milosevic-Stevanovic","year":"2016","unstructured":"Milosevic-Stevanovic, J. et al. Preeclampsia with and without intrauterine growth restriction-two pathogenetically different entities?. Hypertens. Pregnancy 35, 573\u2013582 (2016).","journal-title":"Hypertens. Pregnancy"},{"key":"68842_CR35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ni.2987","volume":"15","author":"N Branzk","year":"2014","unstructured":"Branzk, N. et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat. Immunol. 15, 1017\u20131025 (2014).","journal-title":"Nat. Immunol."},{"key":"68842_CR36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1196\/annals.1368.015","volume":"1075","author":"A Gupta","year":"2006","unstructured":"Gupta, A., Hasler, P., Gebhardt, S., Holzgreve, W. & Hahn, S. Occurrence of neutrophil extracellular DNA traps (NETs) in pre-eclampsia: a link with elevated levels of cell-free DNA?. Ann. N. Y. Acad. Sci. 1075, 118\u2013122 (2006).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"68842_CR37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.placenta.2004.11.007","volume":"27","author":"D Goswami","year":"2006","unstructured":"Goswami, D. et al. Syncytiotrophoblast microparticle shedding is a feature of early onset pre-eclampsia but not normotensive intrauterine growth restriction. Placenta 27, 56\u201361 (2006).","journal-title":"Placenta"},{"key":"68842_CR38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.placenta.2009.11.011","volume":"31","author":"M Messarli","year":"2010","unstructured":"Messarli, M. et al. Fetomaternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta 31, 106\u2013112 (2010).","journal-title":"Placenta"},{"key":"68842_CR39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00404-005-0093-z","volume":"273","author":"AK Gupta","year":"2006","unstructured":"Gupta, A. K., Gebhardt, S., Hillermann, R., Holzgreve, W. & Hahn, S. Analysis of plasma elastase levels in early and late onset preeclampsia. Arch. Gynecol. Obstet. 273, 239\u2013242 (2006).","journal-title":"Arch. Gynecol. Obstet."},{"key":"68842_CR40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/pd.1645","volume":"27","author":"A Crowley","year":"2007","unstructured":"Crowley, A. et al. Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenat. Diagn. 27, 174\u2013179 (2007).","journal-title":"Prenat. Diagn."},{"key":"68842_CR41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000236355","volume":"26","author":"M Al Nakib","year":"2009","unstructured":"Al Nakib, M. et al. Total and fetal cell-free DNA analysis in maternal blood as markers of placental insufficiency in intrauterine growth restriction. Fetal Diagn. Ther. 26, 24\u201328 (2009).","journal-title":"Fetal Diagn. Ther."},{"key":"68842_CR42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3109\/14767050903216033","volume":"23","author":"G Ogge","year":"2010","unstructured":"Ogge, G. et al. Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. Matern. Fetal Neonatal Med. 23, 476\u2013487 (2010).","journal-title":"Matern. Fetal Neonatal Med."},{"key":"68842_CR43","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3390\/jcm8111994","volume":"8","author":"D Formanowicz","year":"2019","unstructured":"Formanowicz, D. et al. Preeclampsia with intrauterine growth restriction generates morphological changes in endothelial cells associated with mitochondrial swelling\u2014an in vitro study. J. Clin. Med. 8, 1994 (2019).","journal-title":"J. Clin. Med."},{"key":"68842_CR44","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.5114\/aoms.2015.56341","volume":"11","author":"A Pokrywka","year":"2015","unstructured":"Pokrywka, A. et al. The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation. Arch. Med. Sci. 11, 1156\u20131163 (2015).","journal-title":"Arch. Med. Sci."},{"key":"68842_CR45","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/ATVBAHA.113.301627","volume":"33","author":"JI Borissoff","year":"2013","unstructured":"Borissoff, J. I. et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler. Thromb. Vasc Biol. 33, 2032\u20132040 (2013).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"68842_CR46","doi-asserted-by":"crossref","first-page":"H1389","DOI":"10.1152\/ajpheart.00298.2003","volume":"286","author":"PK Agatisa","year":"2004","unstructured":"Agatisa, P. K. et al. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am. J. Physiol. Heart Circ. Physiol. 286, H1389\u2013H1393 (2004).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"68842_CR47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/01.HYP.0000251522.18094.d4","volume":"49","author":"AM Germain","year":"2007","unstructured":"Germain, A. M. et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events?. Hypertension. 49, 90\u201395 (2007).","journal-title":"Hypertension."},{"key":"68842_CR48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa0706790","volume":"359","author":"BE Vikse","year":"2008","unstructured":"Vikse, B. E., Irgens, L. M., Leivestad, T., Skjaerven, R. & Iversen, B. M. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med. 359, 800\u2013809 (2008).","journal-title":"N. Engl. J. Med."},{"key":"68842_CR49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/bmj.326.7394.845","volume":"326","author":"BJ Wilson","year":"2003","unstructured":"Wilson, B. J. et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 326, 845 (2003).","journal-title":"BMJ"},{"key":"68842_CR50","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0140-6736(05)67726-4","volume":"366","author":"JG Ray","year":"2005","unstructured":"Ray, J. G., Vermeulen, M. J., Schull, M. J. & Redelmeier, D. A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366, 1797\u20131803 (2005).","journal-title":"Lancet"},{"key":"68842_CR51","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1161\/CIRCULATIONAHA.110.948455","volume":"122","author":"Y Yinon","year":"2010","unstructured":"Yinon, Y. et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 122, 1846\u20131853 (2010).","journal-title":"Circulation"},{"key":"68842_CR52","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/AOG.0000000000002708","volume":"132","author":"ACOG","year":"2018","unstructured":"ACOG. ACOG committee opinion no. 743: low-dose aspirin use during pregnancy. Obstet. Gynecol. 132, e44\u2013e52 (2018).","journal-title":"Obstet. Gynecol."},{"key":"68842_CR53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajog.2017.11.561","volume":"218","author":"S Roberge","year":"2018","unstructured":"Roberge, S., Bujold, E. & Nicolaides, K. H. Aspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis. Am. J. Obstet. Gynecol. 218, 287\u2013293 (2018).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"68842_CR54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lpm.2018.11.022","volume":"48","author":"A Atallah","year":"2019","unstructured":"Atallah, A. et al. Aspirin and preeclampsia. Presse Med. 48, 34\u201345 (2019).","journal-title":"Presse Med."},{"key":"68842_CR55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.6065\/apem.2014.19.3.146","volume":"19","author":"JS Lim","year":"2014","unstructured":"Lim, J. S. et al. New Korean reference for birth weight by gestational age and sex: data from the Korean Statistical Information Service (2008\u20132012). Ann. Pediatr. Endocrinol. Metab. 19, 146\u2013153 (2014).","journal-title":"Ann. Pediatr. Endocrinol. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68842-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:57:04Z","timestamp":1670335024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68842-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68842"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68842-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"14 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11848"}}